

# Subject Index to Volume 6

Abs = Abstract

- Acetylcholine**  
cholinergic drugs, 75 (Feb) Abs  
dopaminergic drugs, 75 (Feb) Abs  
neostriatal, 75 (Feb) Abs  
serotonergic drugs, 75 (Feb) Abs
- Action Potentials**  
effect of temperature on, 378 (Aug) Abs
- Akinesia**  
neo-striatal dopaminergic activity, 87 (Feb) Abs
- Akinesis**  
neostriatum, 73 (Feb) Abs  
nucleus accumbens, 73 (Feb) Abs
- Albumin**  
content in vasogenic brain edema, 423 (Nov)
- Alexia**  
literal, verbal and sentence, 399 (Aug) Abs
- Allergy**  
brain, 394 (Aug) Abs
- Aluminum**  
neurotoxicity of, 391 (Aug) Abs
- Alzheimer's Disease**  
paired helical filaments, 391 (Aug) Abs
- Amantadine**  
versus bromocriptine, 83 (Feb) Abs
- Amino Acid**  
dicarboxylic, 263 (May)  
in Friedreich's ataxia brains, 255 (May)  
in thiamine-deficient encephalopathy, 217 (May)  
uptake in Friedreich's ataxia, 263 (May)  
uptake in normals, 263 (May)
- Anastomoses**  
technique of rapid procedure, 387 (Aug) Abs  
transdural and craniotomy, 387 (Aug) Abs
- Aneurysm**  
carotid and occlusion of internal carotid artery, 390 (Aug) Abs  
cerebral, 441 (Nov)  
cerebral blood flow measurement, 390 (Aug) Abs  
preoperative management of, 441 (Nov)
- Apraxia**  
congenital oculomotor, 398 (Aug) Abs
- Arteriovenous**  
malformation and cerebral blood flow, 441 (Nov)
- Arteriovenous Malformation**  
embolization of, 383 (Aug) Abs
- Artery**  
anastomosis, 378 (Aug) Abs  
carotid atheroma, 133 (May)  
carotid injury and intraoral trauma, 392 (Aug) Abs  
carotid occlusion and anticoagulant treatment, 390 (Aug) Abs  
dissection of internal carotid, 389 (Aug) Abs  
extracranial surgery, 378 (Aug) Abs  
internal carotid occlusion, 378 (Aug) Abs
- Ataxia**  
autosomal recessive, 177 (May)  
Charlevoix-Saguenay 177 (May)  
Charlevoix-Saguenay 185 (May)  
Charlevoix-Saguenay 199 (May)  
C T Scan of posterior fossa, 195 (May)  
Friedreich's and HLA typing, 451 (Nov)  
hereditary, 195 (May)  
measurement of in the rat, 209 (May)  
neuropathy, 199 (May)  
oculomotor findings in, 177 (May)  
vestibular findings in, 177 (May)
- Atheroma**  
carotid artery, 133 (May)
- Atrophy**  
spinal muscular congenital, 379 (Aug) Abs
- Atropine**  
cortical kindling, 47 (Feb)
- Auditory Thresholds**  
and simulated sonic booms, 400 (Aug) Abs
- Autoradiography**  
basal ganglia, 79 (Feb) Abs  
red nucleus, 79 (Feb) Abs  
substantia nigra, 79 (Feb) Abs
- Baboon**  
induced seizures, 129 (May)
- Baclofen**  
in spasticity and multiple sclerosis, 351 (Aug)
- Barbiturate**  
neuronal changes and acute global ischemia, 382 (Aug) Abs
- Basal Ganglia**  
dysfunction and arm movement, 81 (Feb) Abs  
neuronal activity during limb movements, 79 (Feb) Abs
- Beta-Alanine**  
in skin fibroblasts in Friedreich's ataxia, 251 (May)
- Blood-Brain Barrier**  
423 (Nov)
- Blood Flow**  
cerebral and effective age, 391 (Aug) Abs  
cerebral in arteriovenous malformation, 411 (Nov)  
regional spinal cord, 394 (Aug) Abs
- Brain**  
age-related changes, 76 (Feb) Abs  
cholinesterases, 75 (Feb) Abs  
monamines, 76 (Feb) Abs  
resuscitation, 71 (Feb)  
synapses, 75 (Feb) Abs  
vasogenic edema, 423 (Nov)
- Brain Lesions**  
Friedreich's ataxia, 173 (May)
- Bromocriptine**  
dyskinesia, 76 (Feb) Abs  
dystonia, 76 (Feb) Abs  
versus amantadine, 83 (Feb) Abs
- Cancer**  
metastatic and fracture dislocation of the spine, 386 (Aug) Abs
- Cardiac**  
syncope, 7 (Feb)
- Cardiomyopathy**  
in hamster, 223 (May)
- Cardiopulmonary Disease**  
in Friedreich's ataxia, 151 (May)
- Cardiovascular Evaluation**  
Friedreich's ataxia, 147 (May)
- Carnitine Palmytil Transferase**  
cold-induced rhabdomyolysis, 367 (Aug)  
deficiency, 367 (Aug)
- Cataplexy**  
gamma-hydroxybutyrate, 1 (Feb)
- Catecholaminergic**  
innervation, 90 (Feb) Abs
- Caudate Nucleus**  
voluntary movement, 85 (Feb) Abs
- Cauda Equina**  
compression and acute lumbar disc disease, 395 (Aug) Abs
- Cerebellum**  
diseases of and sodium valproate, 455 (Nov)  
stimulation and respiratory coordination, 398 (Aug) Abs
- Cerebral**  
blood flow in arteriovenous malformation, 411 (Nov)
- Cerebral Cortex**  
acetylcholine-amine interactions, 81 (Feb) Abs  
tremor mechanism, 81 (Feb) Abs
- Cerebral Palsy**  
head position control, 399 (Aug) Abs
- Cerebrotendinous Xanthomatosis**  
defective bile acid metabolism, 395 (Aug) Abs
- Charcot-Marie Tooth Disease**  
leucine incorporation, 53 (Feb)
- Charlevoix-Saguenay**  
citrate synthase, 241 (May)  
EEG findings, 191 (May)  
in fibroblasts, 241 (May)  
lipoamide dehydrogenase, 241 (May)  
pyruvate dehydrogenase, 241 (May)  
spastic ataxia, 177 (May)
- Children**  
cerebral tumors, 329 (Aug)
- Choline**  
cholinergic drugs, 75 (Feb) Abs  
neostriatal, 75 (Feb) Abs  
serotonergic drugs, 75 (Feb) Abs
- Circling**  
substantia nigra, 75 (Feb) Abs
- Citrate Synthase**  
Charlevoix-Saguenay ataxia, 241 (May)  
Friedreich's ataxia, 241 (May)
- Cockroach**  
taurine and GABA, 243 (May)
- Coma**  
non-traumatic in children, 382 (Aug) Abs
- Compression**  
spinal cord and early treatment, 394 (Aug) Abs
- Conduction Velocity**  
ulnar nerve, 403 (Nov)
- Corpus Callosum**  
familial agenesis and neuropathy, 400 (Aug) Abs

- Corpus Striatum**  
localization of acetylcholinesterase, 78 (Feb) Abs
- Cortisol**  
in multiple sclerosis, 59 (Feb)
- Cranio-Pharyngeal Canal**  
persistent, 380 (Aug) Abs
- Craniopharyngioma**  
giant cystic, 363 (Aug)
- C T Scan**  
posterior fossa in hereditary ataxias, 195 (May)
- Cubital Tunnel**  
syndrome, 403 (May)
- Cubital Tunnel Syndrome**  
EMG evaluation, 378 (Aug) Abs
- Cysticercosis**  
cerebral, 371 (Aug)
- Cysts**  
cerebral and meningiomas, 386 (Aug) Abs
- Deficiency**  
carnitine palmytil transferase, 367 (Aug)  
cold-induced rhabdomyolysis, 367 (Aug)
- Dementia**  
microvascular morphometry in hippocampal cortex, 390 (Aug) Abs
- Denervation**  
forearm muscle metabolism, 105 (May)
- Diabetes Mellitus**  
peripheral neuropathy, 398 (Aug) Abs
- Diaphragm**  
pacing, 386 (Aug) Abs
- Diphenylhydantoin**  
pulmonary function, 21 (Feb)
- Discoideotomy**  
cervical, 387 (Aug) Abs
- Dopamine**  
enkephalin neurons, 79 (Feb) Abs  
GABA, 79 (Feb) Abs  
glutamate, 79 (Feb) Abs  
pathways, 79 (Feb) Abs
- Dopamine Blockade**  
92 (Feb) Abs
- Dopamine Receptors**  
anterior pituitary, 82 (Feb) Abs  
blocking agents, 73 (Feb) Abs  
pharmacology of, 87 (Feb) Abs  
presynaptic and postsynaptic effect, 73 (Feb) Abs
- Dopler Scanning**  
in cerebrovascular disease, 392 (Aug) Abs
- Duchenne Dystrophy**  
leucine incorporation, 53 (Feb)
- Dyskinesia**  
central monamine functions, 90 (Feb) Abs  
choline, 80 (Feb) Abs  
EMG activity, 74 (Feb) Abs  
L-Dopa, 74 (Feb) Abs  
L-dopa induced, 82 (Feb) Abs  
lecithin, 80 (Feb) Abs  
neuroendocrine modulation, 91 (Feb) Abs  
new drugs in the management of, 89 (Feb) Abs  
"on-off" phenomenon, 80 (Feb) Abs  
spinal reflexes, 74 (Feb) Abs  
stereotaxic target, 90 (Feb) Abs  
tardive, 80 (Feb) Abs  
tardive, 91 (Feb) Abs
- Dyskinesias**  
cortico-bulbar fibers, 75 (Feb) Abs  
stereotactic targets, 75 (Feb) Abs
- Dystonia**  
cortico-bulbar fibers, 75 (Feb) Abs  
musculorum deformans, 87 (Feb) Abs  
stereotactic targets, 75 (Feb) Abs  
Westphal phenomenon, 74 (Feb) Abs
- Dystonic Syndromes**  
essential tremor, 74 (Feb) Abs
- Dystrophy**  
Duchenne muscular, 355 (Aug)  
infantile neuroaxonal, 389 (Aug) Abs  
neonatal myotonic, 379 (Aug) Abs  
preclinical Duchenne, 397 (Aug) Abs
- Edema**  
brain, 423 (Nov)  
tissue albumin, 423 (Nov)  
vasogenic, 423 (Nov)  
water content, 423 (Nov)
- EEG Abnormalities**  
Friedreich's ataxia, 191 (May)  
spastic ataxia of Charlevoix-Saguenay, 191 (May)
- Electrokymograph**  
myoclonic epilepsy, 65 (Feb)
- Electromyography**  
185 (May)  
Charlevoix-Saguenay ataxia, 185 (May)  
Friedreich's ataxia, 185 (May)  
nerve conduction studies, 185 (May)
- Electrophysiological**  
quantitation of cubital tunnel syndrome, 403 (Nov)
- EMG**  
ulnar nerve lesions, 403 (Nov)
- Encephalitis**  
powassan, 396 (Aug) Abs
- Encephalopathy**  
amino acid changes in, 217 (May)  
thiamine-deficient, 217 (May)  
thiamine-deficient, 393 (Aug) Abs
- Endarterectomy**  
carotid, 377 (Aug) Abs  
carotid and stroke prevention, 390 (Aug) Abs  
cerebral blood flow monitoring during carotid, 389 (Aug) Abs
- Entrapment**  
ulnar nerve, 403 (Nov)
- Epilepsy**  
electrokymographic observations, 65 (Feb)  
maternal and birth defects, 377 (Aug) Abs  
myoclonic, 65 (Feb)  
pregnancy, 345 (Aug)  
status and barbiturates, 386 (Aug) Abs  
twilight state, 385 (Aug) Abs
- Ergot Alkaloids**  
antiparkinsonian effect, 80 (Feb) Abs
- Erythrocyte**  
Friedreich's ataxia, 291 (May)  
insulin receptors in Friedreich's ataxia, 233 (May)  
membrane lipids, 291 (May)  
membrane proteins in Friedreich's ataxia, 295 (May)  
protoporphyrin levels in ataxia, 227 (May)
- Extrapyramidal Disorders**  
dopamine agonist, 76 (Feb) Abs  
gaba and dopamine neurons, 74 (Feb) Abs  
hyperkinetic, 76 (Feb) Abs  
therapeutic approaches, 74 (Feb) Abs
- Extrapyramidal System**  
dendroaxonal communication, 84 (Feb) Abs  
estrogen, 74 (Feb) Abs  
progesterone, 74 (Feb) Abs
- Fatty Acids**  
in Friedreich's ataxia, 275 (May)
- Fibers**  
vagal sensory and the area subpostrema, 393 (Aug) Abs
- Fibroblasts**  
dicarboxylic amino acid uptake, 263 (May)  
dicarboxylic aminoaciduria, 263 (May)  
Friedreich's ataxia, 263 (May)
- Foramen Magnum**  
extradural tumours of, 387 (Aug) Abs
- Fracture**  
neck and diving, 388 (Aug) Abs
- Friedreich's Ataxia**  
amino acid distribution, 255 (May)  
beta-alanine in human skin fibroblasts, 251 (May)  
brain lesions, 173 (May)  
brain neurotransmitter receptors, 259 (May)  
cardiomyopathy in hamster, 223 (May)  
cardiopulmonary involvement, 151 (May)  
cardiovascular evaluation, 147 (May)  
citrate synthase, 241 (May)  
dicarboxylic amino acid uptake, 263 (May)  
EEG findings, 191 (May)  
electromyography, 185 (May)  
erythrocyte insulin receptors, 233 (May)  
erythrocyte membrane lipids, 291 (May)  
erythrocyte membrane proteins, 295 (May)  
erythrocyte protoporphyrin levels, 227 (May)  
fatty acid profile, 275 (May)  
fibroblasts, 241 (May)  
glucose tolerance, 233 (May)  
hemagglutination by lectins, 299 (May)  
HLA typing, 451 (Nov)  
in Rimouski, 205 (May)  
linoleic acid content, 275 (May)  
lipoamide dehydrogenase, 241 (May)  
membranes, 285 (May)  
nerve conduction studies, 185 (May)  
obligate heterozygotes, 147 (May)  
oculomotor abnormalities, 167 (May)  
overview, 311 (May)  
plasma lipoproteins, 275 (May)  
pyruvate dehydrogenase, 241 (May)  
regulation of respiration, 159 (May)  
taurine in skin fibroblasts, 251 (May)  
transport mechanisms, 285 (May)
- Gaba**  
in therapy, 92 (Feb) Abs  
levels in parkinson's disease, 88 (Feb) Abs  
pre and post-synaptic effects in cockroach, 243 (May)  
regional receptor binding, 88 (Feb) Abs  
sodium valproate, 455 (Nov)
- Gamma-Hydroxybutyrate**  
cataplexy, 1 (Feb)  
narcolepsy, 1 (Feb)
- Glioma**  
preoperative chemotherapy, 377 (Aug) Abs
- Globus Pallidus**  
functional organization in monkey, 77 (Feb) Abs

- initiation and execution of directed movement, 91 (Feb) Abs  
spontaneous activity, 78 (Feb) Abs  
striatal dopaminergic mechanisms, 78 (Feb) Abs
- Glucose Tolerance**  
Friedreich's ataxia, 233 (May)
- Glutamic Acid**  
basal ganglia, 86 (Feb) Abs  
neurotransmitter, 86 (Feb) Abs
- Growth Hormone**  
on levodopa effects, 87 (Feb) Abs
- Hamster**  
cardiomyopathy, 223 (May)
- Hemagglutination**  
lectins in Friedreich's ataxia, 299 (May)
- Hematoma**  
spontaneous intracerebellar, 392 (Aug) Abs
- Hemiplegia**  
EMG responses, 384 (Aug) Abs
- Hemorrhage**  
subarachnoid and antifibrinolytic therapy, 392 (Aug) Abs
- HLA Frequencies**  
Friedreich's ataxia, 451 (Nov)
- Huntington's Chorea**  
Gaba, 83 (Feb) Abs  
3-H-Gaba, 83 (Feb) Abs
- Huntington's Disease**  
biochemical pathology, 84 (Feb) Abs  
kainic acid model, 84 (Feb) Abs
- Hydrocephalus**  
normal pressure and shunting, 390 (Aug) Abs  
volume-pressure studies, 383 (Aug) Abs
- Hyperhidrosis**  
sympathectomy, 380 (Aug) Abs
- Hyperkinetic Syndrome**  
acetylcholine, 89 (Feb) Abs  
dopamine, 89 (Feb) Abs  
GABAmine, 89 (Feb) Abs  
induced by d-Tubocurarine, 89 (Feb) Abs
- Hyperthermia**  
malignant, 389 (Aug) Abs
- Hyperventilation**  
DC potential shifts, 380 (Aug) Abs
- Hypotension**  
cerebral and cardiac responses to nitroprusside controlled, 382 (Aug) Abs  
orthostatic, 7 (Feb)
- Hypotonia**  
motor control, 90 (Feb) Abs
- Immigration**  
neurological disorders and, 399 (Aug) Abs
- Immunocytochemistry**  
axon terminals, 88 (Feb) Abs  
extrapyramidal system, 88 (Feb) Abs  
GABAergic neurons, 88 (Feb) Abs
- Indians**  
Canadian and methylmercury poisoning, 417 (Nov)
- Infarction**  
cerebellar, 389 (Aug) Abs
- Infection**  
spinal epidural, 325 (Aug)
- Infrasound**  
effect on humans, 400 (Aug) Abs
- Innervation**  
density of skin, 437 (Nov)  
trigeminal, 95 (May)
- Intracranial Pressure**  
monitoring and fiber-optic transducer, 386 (Aug) Abs
- Involuntary Movement**  
drug induced, 75 (Feb) Abs  
management of, 75 (Feb) Abs
- Ischemia**  
cerebral and blood volume expansion and hypertension, 381 (Aug) Abs
- Kainic Acid**  
behavioral effects of, 77 (Feb) Abs  
rat striatum, 77 (Feb) Abs
- Kindling**  
atropine, 47 (Feb)  
cortical, 47 (Feb)  
generalized seizures arising from, 385 (Aug) Abs  
reserpine, 47 (Feb)  
2-deoxy-glucose metabolism, 385 (Aug) Abs
- L-Dopa**  
dyskinesia, 76 (Feb) abs  
dyskinesias and ventromedial tegmental lesions, 85 (Feb) Abs  
dystonia, 76 (Feb) Abs  
functional activity of monoamine oxidase, 92 (Feb) Abs
- Lectins**  
hemagglutination in Friedreich's ataxia, 299 (May)
- Leucine**  
Charcot-Marie Tooth Disease, 53 (Feb)  
Duchenne dystrophy, 53 (Feb)
- Leukodystrophy**  
globoid, 397 (Aug) Abs
- Leukoencephalopathy**  
cerebellar form of, 123 (May)  
progressive multifocal 123 (May)
- Levodopa**  
long-term therapy, 88 (Feb) Abs  
pharmacological correlations, 88 (Feb) Abs  
treatment of parkinson's disease, 88 (Feb) Abs  
tremor and responses to, 90 (Feb) Abs  
with fentiazac, 88 (Feb) Abs
- Limbic System**  
extrapyramidal system, 87 (Feb) Abs  
topographical relationships, 87 (Feb) Abs
- Lipid Storage Disease**  
with cerebellar degeneration, neuropathy and splenomegaly, 391 (Aug) Abs
- Lipoamide Dehydrogenase**  
Charlevoix-Saguenay ataxia, 241 (May)  
Friedreich's ataxia, 241 (May)
- Lipoproteins**  
in Friedreich's ataxia, 275 (May)
- Locomotion**  
substantia nigra, 75 (Feb) Abs
- Locus Coeruleus**  
function, 27 (Feb)  
histopathology, 27 (Feb)  
histopathology, 113 (May)  
neurochemistry, 27 (Feb)  
neurochemistry, 113 (May)
- Lymphomas**  
of the central nervous system, 396 (Aug) Abs
- Lysophosphatidyl Choline**  
peripheral nerve fiber demyelination, 397 (Aug) Abs
- Malformation**  
arteriovenous and cerebral blood flow, 411 (Nov)
- Management**  
preoperative of cerebral aneurysms, 441 (Nov)
- Manpower Planning**  
in neurology, 399 (Aug) Abs
- Melanin**  
in neurofibroma, 139 (May)
- Meningitis**  
CSF lactate levels, 382 (Aug) Abs
- Mercury**  
intoxication of the nervous system, 397 (Aug) Abs
- Metabolism**  
denervation, 105 (May)  
forearm, 105 (May)
- Methylmercury**  
poisoning in Canadian Indians, 417 (Nov)
- Migraine**  
borderland of, 399 (Aug) Abs
- Mitochondria**  
clear vesicles, 91 (Feb) Abs  
dense-core vesicles, 91 (Feb) Abs
- Motor Units**  
altered motor control, 83 (Feb) Abs
- Movement**  
drug induced involuntary, 92 (Feb) Abs  
involuntary, 85 (Feb) Abs  
motor effects, 85 (Feb) Abs  
stress effects, 85 (Feb) Abs
- Movement Disorder**  
familial, 391 (Aug) Abs
- Multiple Sclerosis**  
acute psychosis, 382 (Aug) Abs  
antibody to proteolipid, 385 (Aug) Abs  
baclofen, 351 (Aug)  
blink and jaw jerk reflexes, 398 (Aug) Abs  
clinical prognostic markers, 382 (Aug) Abs  
contrast sensitivity in, 384 (Aug) Abs  
myelin basic protein, 385 (Aug) Abs  
oligoclonal banding and polyacrylamide gel, 396 (Aug) Abs  
orientation-specific contrast sensitivity, 381 (Aug) Abs  
painful tonic seizures, 359 (Aug)  
plasma cortisol, 59 (Feb)  
response to mitogens and specific antigens in, 393 (Aug) Abs  
somatosensory responses, 384 (Aug) Abs  
spinal and cortical evoked potentials, 384 (Aug) Abs  
treatment of spasticity, 351 (Aug)
- Muscle Disease**  
multicore, 379 (Aug) Abs
- Myelopathy**  
hypoxic, 380 (Aug) Abs
- Myoclonus**  
postanoxic intention, 39 (Feb)  
valproic acid, 39 (Feb)
- Myopathy**  
mitochondrial, 378 (Aug) Abs

- muscular rigidity and respiratory failure, 379 (Aug) Abs  
oculoskeletal and abnormal mitochondria, 378 (Aug) Abs
- Myotonia**  
dystrophica and glucose transport and oxidation, 388 (Aug) Abs
- Myotonic**  
dystrophy partial, 388 (Aug) Abs
- Narcolepsy**  
gamma-hydroxybutyrate, 1 (Feb)
- Neostriatum**  
cholinergic excitation, 84 (Feb) Abs  
nicotinic receptor, 84 (Feb) Abs  
rat, 84 (Feb) Abs
- Nephrotic Syndrome**  
seizures and Friedreich's ataxia, 397 (Aug) Abs
- Nerve**  
axillary and shoulder trauma, 388 (Aug) Abs  
dorsal motor nucleus of vagus, 395 (Aug) Abs  
ulnar, 403 (Nov)
- Nerve Conduction Studies**  
Charlevoix-Saguenay ataxia, 185 (May)  
Friedreich's ataxia, 185 (May)
- Nerve Growth Factor**  
transport of, 379 (Aug) Abs
- Neuralgia**  
trigeminal and rhizotomy and microvascular decompression, 383 (Aug) Abs
- Neurite Outgrowth**  
ontogeny and distribution of, 395 (Aug) Abs
- Neuritis**  
experimental allergic and demyelinating activity, 380 (Aug) Abs
- Neurofibroma**  
melanin containing, 319 (May)
- Neuroma**  
management of acoustic, 380 (Aug) Abs
- Neurons**  
medial hypothalamic and amino acids, 395 (Aug) Abs
- Neuropathy**  
Charlevoix-Saguenay ataxia, 199 (May)  
Cis-platinum, 378 (Aug) Abs  
Dejerine-Sottas, 388 (Aug) Abs
- Nuclei**  
anterior cerebellum, 89 (Feb) Abs  
catecholaminergic, 89 (Feb) Abs  
interconnections, 89 (Feb) Abs
- Nucleus**  
entependuncular, 80 (Feb) Abs
- Nucleus Subthalamicus**  
afferents to, 88 (Feb) Abs
- Oculomotor Abnormality**  
Friedreich's ataxia, 167 (May)  
in spastic ataxia of Charlevoix-Saguenay, 177 (May)
- On-Off Responses**  
84 (Feb) Abs
- Pain**  
denervation and thalamic stimulation, 384 (Aug) Abs
- Paralysis**  
tourniquet and conduction abnormalities, 381 (Aug) Abs
- Paraplegia**  
arachnoid cyst and meningioma, 387 (Aug) Abs
- Parkinsonism**  
bromocriptine, 73 (Feb) Abs  
dopaminergic drugs, 81 (Feb) Abs  
familial fatal, 400 (Aug) Abs  
mortality with levodopa, 77 (Feb) Abs  
mortality with sinemet, 77 (Feb) Abs  
neurotransmitter changes, 81 (Feb) Abs  
plasmarenin, 73 (Feb) Abs  
rigidity, 85 (Feb) Abs  
10 year follow-up, 84 (Feb) Abs  
treated with L-dopa, 84 (Feb) Abs  
tremor of neck muscles, 85 (Feb) Abs
- Parkinson's Disease**  
akinesia, 89 (Feb) Abs  
beta adrenergic blocking agents, 79 (Feb) Abs  
brain phospholipids, 76 (Feb) Abs  
bromocriptine, 82 (Feb) Abs  
bromocriptine, 396 (Aug) Abs  
catecholamine enzymes, 85 (Feb) Abs  
control of ramp movements, 89 (Feb) Abs  
control of voluntary ballistic movements, 89 (Feb) Abs  
CSF tetrahydrobiopterin levels, 91 (Feb) Abs  
deprenyl, 76 (Feb) Abs  
disturbances of rhythm formation, 85 (Feb) Abs  
GABA, 83 (Feb) Abs  
increased symptoms and levodopa toxicity, 78 (Feb) Abs  
lergotrile, 82 (Feb) Abs  
lergotrile in the treatment, 92 (Feb) Abs  
levodopa therapy, 88 (Feb) Abs  
limb displacement, 78 (Feb) Abs  
movement related macropotentials, 86 (Feb) Abs  
single motor unit discharge patterns, 92 (Feb) Abs  
sodium valproate, 337 (Aug)  
sympathetic ganglion cell antibodies, 87 (Feb) Abs  
3H-GABA, 83 (Feb) Abs  
tremor and arm displacement, 91 (Feb) Abs
- Parkinson's Syndrome**  
principles and problems of therapy, 75 (Feb) Abs
- Pathway**  
subthalamo-nigral, 80 (Feb) Abs
- Phenytoin**  
protein binding of valproic acid, 453 (Nov)
- Pituitary Apoplexy**  
381 (Aug) Abs
- Poisoning**  
methylmercury in Canadian Indians, 417 (Nov)
- Polyneuropathy**  
infantile mixed, 397 (Aug) Abs  
myxedematous, 398 (Aug) Abs
- Potentials**  
respiratory evoked, 380 (Aug) Abs
- Pregnancy**  
epilepsy, 345 (Aug)
- Primate Basal Ganglia**  
cytohistochemical study, 83 (Feb) Abs
- Protein Synthesis**  
355 (Aug)  
in Duchenne muscular dystrophy, 355 (Aug)  
in patients and carriers, 355 (Aug)
- Proteins**  
analysis of erythrocyte membrane, 394 (Aug) Abs  
binding of by valproic acid, 453 (Nov)
- Pulmonary Function**  
diphenylhydantoin, 21 (Feb)
- Pyruvate Dehydrogenase**  
Charlevoix-Saguenay ataxia, 241 (May)  
Friedreich's ataxia, 241 (May)
- Radiation**  
therapy causing glioblastoma, 388 (Aug) Abs
- Radiculopathy**  
fibroid, 396 (Aug) Abs
- Receptors**  
neurotransmitter in Friedreich's ataxia, 259 (May)
- Recognition**  
letters and faces with sensory deficit, 381 (Aug) Abs
- Reflex**  
depressor, 95 (May)  
diving, 95 (May)  
naso-cardiorespiratory, 95 (May)  
oculocardiac, 95 (May)
- Regeneration**  
primary aberrant, 398 (Aug) Abs
- Reserpine**  
cortical kindling, 47 (Feb)
- Respiration**  
Friedreich's ataxia, 159 (May)
- Resuscitation**  
brain, 71 (Feb)
- Retina**  
function and light deprived animals, 393 (Aug) Abs
- Rhabdomyolysis**  
carnitine palmytyl transferase deficiency, 367 (Aug)  
cold-induced, 367 (Aug)
- Rigidity**  
motor cortical neuron response, 90 (Feb) Abs  
neostriatum, 73 (Feb) Abs  
nucleus accumbens, 73 (Feb) Abs  
phenothiazine, 90 (Feb) Abs
- Rimouski**  
Friedreich's ataxia, 205 (May)
- Schwann Cell**  
origin of melanin, 139 (May)
- Seizures**  
akinetic, 7 (Feb)  
forebrain commissurotomy, 385 (Aug) Abs  
painful tonic in multiple sclerosis, 359 (Aug)  
photoically induced, 129 (May)  
Vitamin E, 43 (Feb)
- Shunt**  
cerebrospinal fluid, 69 (Feb)  
subcutaneous placement introducer, 69 (Feb)
- Skin**  
glabrous, 437 (Nov)  
reinnervation, 437 (Nov)
- Skin Innervation**  
central and peripheral factors, 437 (Nov)

- Sleep**  
 gamma-hydroxybutyrate, 1 (Feb)  
 nocturnal, 1 (Feb)  
 non-REM and H-reflex, 384 (Aug) Abs
- Sodium Valproate**  
 cerebellar disorders, 455 (Nov)  
 GABA, 455 (Nov)  
 parkinson's disease, 337 (Aug)  
 seizures in children, 385 (Aug) Abs
- Spasmodic Torticollis**  
 neuropharmacological investigation, 82 (Feb)  
 Abs  
 pathophysiology of, 427 (Nov)  
 pharmacotherapy, 427 (Nov)
- Spasticity**  
 baclofen, 351 (Aug)
- Spinal**  
 epidural infection, 325 (Aug)
- Spinal Cord**  
 compression and early treatment, 394 (Aug)  
 Abs  
 sciatic nerve grafting, 394 (Aug) Abs  
 sciatic nerve grafting, 395 (Aug) Abs
- Startle Disorders of Man**  
 389 (Aug) Abs
- Stenosis**  
 cervical, 387 (Aug) Abs
- Stereotaxic**  
 applications, 87 (Feb) Abs
- Striatum**  
 acetylcholine, 77 (Feb) Abs  
 dopamine, 77 (Feb) Abs  
 dopamine release, 79 (Feb) Abs  
 estrogens, 77 (Feb) Abs  
 levodopa treatment, 81 (Feb) Abs  
 membrane dopamine binding, 81 (Feb) Abs  
 nigral relationship, 81 (Feb) Abs  
 presynaptic control of, 79 (Feb) Abs  
 rat, 77 (Feb) Abs  
 synapses of, 80 (Feb) Abs  
 transmitters of, 80 (Feb) Abs
- Stroke**  
 cardiac lesions after, 392 (Aug) Abs  
 pathogenesis of coning, 387 (Aug) Abs
- Substantia Nigra**  
 and striatum connections, 90 (Feb) Abs  
 branched neurons, 77 (Feb) Abs  
 cytohistochemical study, 83 (Feb) Abs  
 dopamine, 86 (Feb) Abs  
 functional organization in monkey, 77 (Feb)  
 Abs  
 localization of acetylcholinesterase, 78 (Feb)  
 Abs
- nigro-striatal dopaminergic neurons, 86 (Feb)  
 Abs  
 output neurons of, 77 (Feb) Abs  
 peripheral input, 78 (Feb) Abs  
 striatal excitation, 84 (Feb) Abs  
 striatal inhibition, 84 (Feb) Abs
- Subthalamic Nucleus**  
 functional organization in monkey, 77 (Feb)  
 Abs
- Subthalamo-Nigral**  
 output neurons, 80 (Feb) Abs  
 pathway, 80 (Feb) Abs
- Surgery**  
 for ulnar nerve entrapment, 403 (Nov)
- Syncope**  
 cardiac, 7 (Feb)  
 orthostatic hypotensive, 7 (Feb)  
 seizure, 7 (Feb)  
 vaso-vagal, 7 (Feb)
- Syndrome**  
 bobble-head doll, 386 (Aug) Abs  
 cubital tunnel, 403 (Nov)  
 electrophysiological quantitation, 403 (Nov)  
 Gerstmann, 377 (Aug) Abs  
 happy puppet, 393 (Aug) Abs
- Synostosis**  
 sagittal and treatment, 383 (Aug) Abs
- Syringomyelia**  
 amipaque myelography, 377 (Aug) Abs  
 lumbo-peritoneal shunt, 383 (Aug) Abs
- Taurine**  
 in skin fibroblasts in Friedreich's ataxia, 251  
 (May)  
 pre and post-synaptic effects in cockroach, 243  
 (May)
- Tetrahydrobiopterin**  
 in human CSF, 82 (Feb) Abs
- Thalamus**  
 centre median, 86 (Feb) Abs  
 intralaminar, 86 (Feb) Abs  
 nuclei, 86 (Feb) Abs
- Therapy**  
 barbiturate, 390 (Aug) Abs
- Thiamine**  
 deficient encephalopathy, 217 (May)
- Tremor**  
 essential, 82 (Feb) Abs  
 experimental and thalamic and precentral  
 cortical neurons, 93 (Feb) Abs  
 parkinsonian, 82 (Feb) Abs  
 production of, 86 (Feb) Abs
- relief of, 86 (Feb) Abs  
 reflex mechanisms, 82 (Feb) Abs
- Thrombosis**  
 vein of Galen, 392 (Aug) Abs
- Trigeminal**  
 innervation, 95 (May)
- Tryptophan**  
 metabolism and anti-parkinsonian drugs, 93  
 (Feb) Abs
- Tumor**  
 pineal in children, 381 (Aug) Abs
- Tumors**  
 cerebral in children, 329 (Aug)  
 malignant peripheral nerve, 377 (Aug) Abs
- Valproic Acid**  
 and plasma levels of phenobarb, 383 (Aug)  
 Abs  
 cerebral indole amine metabolism, 385 (Aug)  
 Abs  
 phenytoin and, 453 (Nov)  
 postanoxic intention myoclonus, 39 (Feb)  
 protein binding, 453 (Nov)  
 protein binding and salivary concentrations,  
 394 (Aug) Abs
- Vasovagal**  
 syncope, 7 (Feb)
- Vestibular Abnormalities**  
 in spastic ataxia of Charlevoix-Saguenay, 177  
 (May)
- Vestibular Damage**  
 noise induced, 400 (Aug) Abs
- Virus**  
 abnormal behavior, 83 (Feb) Abs  
 herpes simplex, 74 (Feb) Abs  
 herpes simplex, 83 (Feb) Abs  
 neurone identification, 74 (Feb) Abs  
 neostriatal injection, 83 (Feb) Abs  
 neostriatum, 74 (Feb) Abs  
 seizures, 83 (Feb) Abs
- Visual Information**  
 arm movement, 76 (Feb) Abs  
 parkinson's disease, 76 (Feb) Abs
- Vitamin E**  
 seizures, 43 (Feb)
- Water**  
 content in vasogenic brain edema, 423 (Nov)
- Xenon 133**  
 inhalation method in arteriovenous  
 malformation, 411 (Nov)